Kev Kho Mob Hepatocellular Carcinoma nrog Bioocus GPC3 CAR-T Therapy

Keeb Kwm ntawm Tus Neeg Mob

Pawan, ib tug neeg mob siab rau los ntawm Is Nrias teb, tau kuaj pom tias muaj kab mob siab ntev uas ua rau muaj ntau yam mob siab (HCC) thaum Lub Yim Hli 2024. Thaum muaj hnub nyoog 67 xyoo thaum kuaj pom (nws yuav muaj hnub nyoog 68 xyoo thaum kho mob), nws tau ntsib ib qho kab mob hnyav uas muaj ntau qhov mob siab, cov cim qog siab xws li AFP thiab PIVKA-II siab, ntshav tsis txaus, cov enzyme siab tsis zoo, thiab tom qab ntawd cov pob txha metastases. Txawm hais tias tau dhau los ntawm kev siv tshuaj transarterial radioembolization (TARE), transarterial chemoembolization (TACE), immunotherapy (Atezolizumab + Bevacizumab, Tremelimumab + Durvalumab), thiab kev kho mob targeted (Lenvatinib, Cabozantinib, Regorafenib), nws tus kab mob tau nce qib. Kev kuaj noob caj noob ces qhia tau tias muaj kev hloov pauv hauv TP53, KRAS, CDKN2A, CTNNB1, thiab ARID1A, nrog rau kev qhia tawm PD-L1 qis thiab HRD tsis zoo, qhia txog kev teb tsawg rau qee yam tshuaj inhibitors. Nrhiav kev daws teeb meem siab heev, Pawan raug xa mus rau Tianjin Cancer Hospital los ntawm Bioocus rau peb txoj kev kho mob GPC3 CAR-T autologous raws li kev kho mob tus lej P1544.

Txoj Kev Kho Mob

Pawan txoj kev kho mob CAR-T pib nrog leukapheresis thaum Lub Yim Hli 11, 2025, tom qab ntawd los ntawm kev tsim khoom thiab infusion thaum Lub Cuaj Hli 2, 2025. Nws tau txais koob tshuaj ntawm 4.73 × 10^8 CAR-T hlwb, tsom mus rau GPC3, ib qho cim overexpressed hauv HCC. Kev kho mob ua ntej infusion suav nrog fludarabine thiab cyclophosphamide los txhim kho engraftment. Tom qab infusion, nws cov ntshav peripheral tau saib xyuas rau CAR-T nthuav dav ntawm Hnub 4 (D4), 7 (D7), 10 (D10), thiab 12 (D12).

• D4 (Cuaj Hlis 6, 2025):Cov qe ntshav CAR-T ntawm 5.15% ntawm CD3+ T qe ntshav (tus nqi tag nrho: 9.27 × 10^6/L), qhia txog kev pib cog noob.
• D7 (Cuaj Hlis 9, 2025):Nce siab tshaj plaws ntawm 3.97% (6.12 × 10^7/L), qhia txog kev loj hlob sai.
• D10 (Cuaj Hlis 12, 2025):04% (9.07 × 10^6/L).
• D12 (Cuaj Hlis 14, 2025):Ruaj khov ntawm 2.82% (2.26 × 10^7/L), nrog rau tag nrho cov T hlwb ntawm 5.4 × 10^9/L, CD3+ ntawm 14.87%, CD8+ cytotoxic T hlwb nce siab ntawm 77.88%, thiab cov pawg CAR-T sib npaug (piv txwv li, 2.46% CD8+CARGPC3+/CD8+).

Thaum lub sijhawm pw hauv tsev kho mob txij lub Yim Hli 11 txog rau lub Cuaj Hlis 15, 2025, Pawan tau muaj cov kev mob tshwm sim me me, suav nrog kub taub hau me me (txog li 38.5 ° C), qaug zog, thiab cov enzyme siab ib ntus, tswj tau zoo yam tsis muaj cytokine tso tawm syndrome hnyav (CRS qib 1) lossis neurotoxicity. Cov cim tseem ceeb tseem ruaj khov, thiab kev saib xyuas txhawb nqa suav nrog kev tiv thaiv kev kis kab mob, kev noj zaub mov zoo, thiab kev saib xyuas cov teeb meem xws li ascites.

Cov Txiaj Ntsig Zoo Tshaj Plaws

Txawm hais tias qhov kev nthuav dav CAR-T me me xwb los, nws tau qhia txog kev ua haujlwm ntev thiab tiv thaiv kab mob qog, sib raug zoo nrog cov cim qog uas ruaj khov thiab tsis muaj kev nce qib tam sim ntawd ntawm kev thaij duab tom qab. Pawan cov ntaub ntawv sib haum nrog Bioocus txoj kev vam meej hauv GPC3 CAR-T rau HCC, qhov twg txawm tias qhov kev ua haujlwm ntev me ntsis tuaj yeem ua rau muaj kev teb ruaj khov rau cov neeg mob uas tsis kho tau. Nws tau tawm hauv tsev kho mob hauv qhov mob ruaj khov rau lub Cuaj Hlis 15, 2025, nrog rau cov lus qhia rau kev saib xyuas tas mus li, suav nrog cov cim qog, kev ua haujlwm ntawm daim siab, thiab PET-CT scans. Txoj kev kho mob no tau txo qis kev lom neeg hauv lub cev thaum kho qhov chaw mob qog.